当前位置:首页 - 行情中心 - 奥翔药业(603229) - 财务分析 - 利润表

奥翔药业

(603229)

  

流通市值:60.49亿  总市值:60.49亿
流通股本:5.93亿   总股本:5.93亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入671,662,047.6468,715,612.42262,549,690.48764,547,389.04
营业收入671,662,047.6468,715,612.42262,549,690.48764,547,389.04
二、营业总成本419,225,427.62285,614,760.36150,656,558.62513,679,534.53
营业成本284,288,563.4196,851,660.2107,933,782.97370,794,875.52
税金及附加4,411,401.133,185,904.83977,917.753,511,405.49
销售费用10,465,661.728,226,022.071,584,617.8420,758,174.13
管理费用78,209,961.6659,596,515.1719,325,874.1693,790,880.73
研发费用73,686,399.247,902,225.0221,462,162.8367,072,731.91
财务费用-31,836,559.49-30,147,566.93-627,796.93-42,248,533.25
其中:利息费用6,032,121.694,089,343.922,148,371.546,106,643.49
其中:利息收入22,091,667.0113,961,983.916,830,594.638,223,066.41
加:公允价值变动收益3,042,877.033,042,877.03-1,954,582.794,946,902.51
加:投资收益5,799,465.05962,114.05944,614.051,380,098.67
资产减值损失(新)-2,378,743.32-2,378,743.32--1,789,822.32
信用减值损失(新)-8,930,581.44-5,251,563.3-2,691,497.15-3,160,028.75
其他收益5,889,866.14,180,106.09810,566.085,469,648.03
营业利润平衡项目0000
四、营业利润255,859,503.4183,655,642.61109,002,232.05257,714,652.65
加:营业外收入427,206.590.9-14,000
减:营业外支出1,687.291,259.3318.981,869,636.04
利润总额平衡项目0000
五、利润总额256,285,022.7183,654,384.18109,002,213.07255,859,016.61
减:所得税费用30,947,389.8823,457,635.8515,329,404.6220,483,189.15
六、净利润225,337,632.82160,196,748.3393,672,808.45235,375,827.46
持续经营净利润225,337,632.82160,196,748.3393,672,808.45235,375,827.46
归属于母公司股东的净利润225,337,632.82160,196,748.3393,672,808.45235,375,827.46
(一)基本每股收益0.380.270.220.59
(二)稀释每股收益0.380.270.220.59
八、其他综合收益83,520.23-21,566.8-36,054.96228,445.32
归属于母公司股东的其他综合收益83,520.23-21,566.8-36,054.96228,445.32
九、综合收益总额225,421,153.05160,175,181.5393,636,753.49235,604,272.78
归属于母公司股东的综合收益总额225,421,153.05160,175,181.5393,636,753.49235,604,272.78
公告日期2023-10-282023-08-302023-04-282023-04-28
审计意见(境内)标准无保留意见
TOP↑